⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Vivasor, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Vivasor, Inc.
↗San Diego, USA
Vivasor, Inc. is a clinical-stage biotechnology company focused on the research and development of advanced therapeutic platforms, including antibody-drug conjugates (ADCs) for oncology indications. The company is closely linked to Oqory, Inc., sharing leadership, operational facilities, and strategic interests in the development of innovative medicines.
The company maintains a complex corporate structure with significant interconnections to other entities such as Scilex Holding Company and Datavault AI. Vivasor is actively involved in licensing agreements and strategic equity investments, positioning itself as a player in the monetization of pharmaceutical intellectual property and clinical-stage drug development.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$50M
Investors:Datavault AI Inc.
PIPELINE
Stage:Clinical
Lead Drug Stage:Clinical
Modalities:Antibody-drug conjugates (ADC), Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Oqory, Inc.
Key Partnerships:Datavault AI (Licensing and equity investment), Scilex Holding Company (Common leadership and partial ownership)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Henry Ji - CEO and President
Scientific Founders:Henry Ji
LINKS
Website:vivasor.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Vivasor, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.